During the past decade, Institute for Drug Development conducted 1 clinical trials. In the 10-year time frame, 1 clinical trials started and 4 clinical trials were completed, i.e. on average, 400% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 1 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Institute for Drug Development" #1 sponsor was "Novartis Pharmaceuticals" with 7 trials, followed by "Daiichi Sankyo, Inc." with 2 trials sponsored, "Enzon Pharmaceuticals, Inc." with 2 trials sponsored, "Hoffmann-La Roche" with 2 trials sponsored and "Millennium Pharmaceuticals, Inc." with 2 trials sponsored. Other sponsors include 14 different institutions and companies that sponsored additional 21 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Institute for Drug Development" #1 collaborator was "Merck KGaA, Darmstadt, Germany" with 1 trials as a collaborator and "National Cancer Institute (NCI)" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 2 trials.

According to Clinical.Site data, the most researched conditions in "Institute for Drug Development" are "Cancer" (5 trials), "Breast Cancer" (3 trials), "Prostate Cancer" (3 trials), "Lymphoma" (2 trials) and "Non-Hodgkin's Lymphoma" (2 trials). Many other conditions were trialed in "Institute for Drug Development" in a lesser frequency.

Most popular intervention types in "Institute for Drug Development" are "Drug" (34 trials) and "Biological" (3 trials). Other intervention types were less common.

The name of intervention was led by "Elesclomol Sodium" (2 trials), "MLN4924" (2 trials), "Placebo" (2 trials), "S-1/Cisplatin" (2 trials) and "exatecan mesylate" (2 trials). Other intervention names were less common.

The vast majority of trials in "Institute for Drug Development" are 30 trials for "All" genders, 2 trials for "Female" genders and 2 trials for "Male" genders.

Currently, there are NaN active trials in "Institute for Drug Development". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 30 completed trials in Institute for Drug Development, 2 suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Institute for Drug Development, 22 "Phase 1" clinical trials were conducted, 13 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".